0001004878-15-000203.txt : 20150630 0001004878-15-000203.hdr.sgml : 20150630 20150630131115 ACCESSION NUMBER: 0001004878-15-000203 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150625 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20150630 DATE AS OF CHANGE: 20150630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 15960820 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 8-K 1 form8kitem502stkop6-15.txt 8-K RE STOCK OPTIONS PER NON-QUALIFIED STK OPTION PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 25, 2015 CEL-SCI CORPORATION ------------------------------------ (Exact name of Registrant as specified in its charter) Colorado 0-11503 84-0916344 ---------------------------- --------------------- -------------------- (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation) Identification No.) 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 ------------------------------------------------ (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (703) 506-9460 N/A ----------------------------- (Former name or former address if changed since last report) 1 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 25, 2015, the Company, pursuant to the provisions of its Non-Qualified Stock Option Plan, granted options to the following officers and/or directors upon the terms shown below: Shares Issuable Upon Exercise Exercise Expiration Name of Option (1) Price Date ---- --------------- -------- --------- Maximilian de Clara 125,000 $0.66 6/21/2025 Peter Young 125,000 $0.66 6/21/2025 Alexander Esterhazy 125,000 $0.66 6/21/2025 Bruno Baillavoine 125,000 $0.66 6/21/2025 (1) Options to purchase the first 41,667 shares will be exercisable on June 22, 2016, options to purchase the next 41,667 shares will be exercisable on June 22, 2017 and options to purchase the remaining 41,666 shares will be exercisable on June 22, 2018. If the option holder ceases to be a director for any reason prior to June 22, 2018, then any options which are not then exercisable will expire. The grant of the options was approved by the Company's Compensation Committee and board of directors. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 29, 2015 CEL-SCI CORPORATION By: /s/ Patricia B. Prichep ------------------------------------- Patricia B. Prichep Senior Vice President of Operations 3